Blood Cancer Awareness Month is a global event helping to raise awareness of one of the world’s most prevalent and dangerous cancers: blood cancer. Every September, Blood Cancer Awareness Month brings attention to leukemia, lymphoma, myeloma, and related blood cancers. In Sweden there is for the first time a Blood cancer day, taking place on September 24th. Raising awareness of blood cancer, its signs and symptoms and its impact, will help to improve early diagnosis, encourage policymakers to prioritise the disease, as well as help everyone with blood cancer feel connected and heard. The purpose of this campaign is to help people recognize symptoms, understand risk factors, learn about treatment options, and see the importance of early detection.
Blood cancer and in particular AML (acute myeloid leukemia), is a key focus for Oxcia. Oxcia has received Orphan Drug Designation for OXC-101 in AML from both FDA and EMA. Oxcia is currently conducting an expansion study, a combined phase I/II study, in a selected group of patients with relapsed/recurrent AML. The treatment is given in combination with one of the standard treatments (idarubicin). The aim of the study is to confirm the promising preliminary effects previously observed, and to lay the foundation for a pivotal phase II study that could form the basis for a regulatory accelerated approval. The medical need for AML is still high and Oxcia’s aim is to bring improved survival & quality of life to patients.
